title: Novel antidiabetic and hypolipidemic agents. 5. Hydroxyl versus benzyloxy containing chroman derivatives.
abstract: Several thiazolidinediones having chroman moieties were synthesized and evaluated for their euglycemic and hypolipidemic activities. Some of the analogues having an aminoalkyl group as a linker between the chroman ring and 4-[5-(2,4-dioxo-1, 3-thiazolidinyl)methyl]phenoxy moiety seem to be better than troglitazone. In vitro transactivation assays of PPARgamma have been carried out with these glitazones to understand their molecular mechanism. For the first time we have found that some of the unsaturated thiazolidinediones are superior to their saturated counterpart in the in vivo assay. A more potent thiazolidinedione analogue than troglitazone is reported. Pharmacokinetic studies have shown that protection of the OH group in the chroman moiety leads to a decrease in metabolism, thereby resulting in a superior pharmacological profile.
authors.affiliation: Medicinal and Organic Chemistry, Clinical Research, Pharmacology, Dr. Reddy's Research Foundation, Bollaram Road, Miyapur, Hyderabad 500 050, India.
authors.forename: K A
authors.initials: KA
authors.lastname: Reddy
authors.forename: B B
authors.initials: BB
authors.lastname: Lohray
authors.forename: V
authors.initials: V
authors.lastname: Bhushan
authors.forename: A S
authors.initials: AS
authors.lastname: Reddy
authors.forename: N V
authors.initials: NV
authors.lastname: Rao Mamidi
authors.forename: P P
authors.initials: PP
authors.lastname: Reddy
authors.forename: V
authors.initials: V
authors.lastname: Saibaba
authors.forename: N J
authors.initials: NJ
authors.lastname: Reddy
authors.forename: A
authors.initials: A
authors.lastname: Suryaprakash
authors.forename: P
authors.initials: P
authors.lastname: Misra
authors.forename: R K
authors.initials: RK
authors.lastname: Vikramadithyan
authors.forename: R
authors.initials: R
authors.lastname: Rajagopalan
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002839:Chromans / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D005260:Female; D007004:Hypoglycemic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000960:Hypolipidemic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D051381:Rats; D017208:Rats, Wistar; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D014157:Transcription Factors / Q000819:agonists; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D002839:Chromans; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D018160:Receptors, Cytoplasmic and Nuclear; D013844:Thiazoles; D014157:Transcription Factors; D014280:Triglycerides